Breaking News

Tweet TWEET

ForteBio Launches New Dip and Read™ Anti-FLAG Biosensor to Facilitate Protein Research and Drug Development

  ForteBio Launches New Dip and Read™ Anti-FLAG Biosensor to Facilitate
  Protein Research and Drug Development

Business Wire

PORT WASHINGTON, N.Y. -- February 12, 2013

ForteBio, a division of Pall Life Sciences and a leading supplier of
label-free technology that accelerates the development of biotherapeutic and
pharmaceutical products, today announced the launch of its new Dip and Read™
Anti-FLAG Biosensor for use on the company’s Octet® and BLItz™ instrumentation
systems. The new biosensor enables researchers to quickly and easily detect
FLAG-tagged recombinant proteins for their quantitation and kinetic
characterization, which are key steps in drug development.

The Dip and Read(TM) Anti-FLAG Biosensor for use on ForteBio's Octet(R) and
BLItz(TM) instrumentatio ...

The Dip and Read(TM) Anti-FLAG Biosensor for use on ForteBio's Octet(R) and
BLItz(TM) instrumentation systems enables researchers to quickly and easily
detect FLAG-tagged recombinant proteins for their quantitation and kinetic
characterization.

“FLAG is a commonly used affinity peptide tag to enable protein detection and
purification,” said Christopher Silva, vice president of marketing for Pall's
ForteBio division. “However, traditional methods for evaluating FLAG-tagged
proteins rely on time-consuming, analytical methods, which can slow down drug
discovery and development. Our new Anti-FLAG Biosensor, together with the
BLItz instrument platform’s ease of use or the Octet system’s high throughput,
is designed to greatly accelerate laboratory workflow, reduce time to results
and increase cost-efficiency.”

The biosensor is pre-immobilized with Sigma-Aldrich’s well-established,
high-affinity ANTI-FLAG® M2 antibody, which has been cited in more than 30,000
journal articles over the last two decades. The high specificity of the
antibody-based biosensor enables the direct quantitation of FLAG-tagged
analytes in crude lysates, column eluents, cell lysates and cell culture
supernatants.

Mr. Silva added that the new biosensor is intended to address strong demand
for direct capture of FLAG-tagged proteins among ForteBio’s Octet customers.
It also should further broaden the appeal of the BLItz instrument platform –
which enables label-free analysis of proteins using small sample volumes on a
benchtop instrument – among academic researchers. “We are now pleased to offer
our customers biosensors for the three most widely used peptide tags – HIS,
GST and FLAG – among pharmaceutical and biotechnology scientists.”

The Octet family of products is based on ForteBio’s proprietary Bio-Layer
Interferometry (BLI) technology. These instruments incorporate disposable
optical Dip and Read biosensors that measure multiple interactions in
parallel, without the use of detection agents. For single-sample analysis,
ForteBio recently launched its BLItz instrument platform. The new platform
revolutionizes the use of label-free protein analysis by making it more
accessible and cost-effective for individual bench scientists in
biotherapeutic discovery, process development and academic research.

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical
systems to accelerate biotherapeutic drug discovery and development. These
systems enable real-time, label-free analysis of biomolecular interactions,
providing information on affinity, kinetics and concentration. ForteBio’s
analytical capabilities enable significantly easier, faster and better
characterization of drug candidates, thus providing greater value in drug
development applications where existing methods have limitations in
throughput, performance and cost. For more information, visit
www.fortebio.com.

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides
cutting-edge products and services to meet the demanding needs of customers
discovering, developing and producing biotech drugs, vaccines and classic
pharmaceuticals. Its membranes and membrane devices optimize detection and
sample preparation in the drug research, clinical diagnostics, genomics, and
proteomics markets. Pall Life Sciences is a leading provider of separation
systems and single-use filtration and purification technologies to
pharmaceutical and biotechnology companies to support faster development of
new drugs and vaccines that are safer and require less energy and water to
produce. Pall Life Sciences’ technologies are also used in clinical
institutions and the food and beverage industries.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification
leader providing solutions to meet the critical fluid management needs of
customers across the broad spectrum of life sciences and industry. Pall works
with customers to advance health, safety and environmentally responsible
technologies. The company’s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a “top green company”
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit
www.pall.com/green.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130212006653/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50561903&lang=en

Contact:

Doug Novarro
Corporate Public Relations, Pall Corporation
516-801-9944
Doug_novarro@pall.com
or
Gemma Milan
ForteBio
650-289-6800
Gemma_milan@pall.com
 
Press spacebar to pause and continue. Press esc to stop.